CN1927175B - Compound recipe anticancer slow release injection comprising tetrazole violet - Google Patents

Compound recipe anticancer slow release injection comprising tetrazole violet Download PDF

Info

Publication number
CN1927175B
CN1927175B CN200610200997A CN200610200997A CN1927175B CN 1927175 B CN1927175 B CN 1927175B CN 200610200997 A CN200610200997 A CN 200610200997A CN 200610200997 A CN200610200997 A CN 200610200997A CN 1927175 B CN1927175 B CN 1927175B
Authority
CN
China
Prior art keywords
acid
tetrazole violet
tetrazole
slow release
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200610200997A
Other languages
Chinese (zh)
Other versions
CN1927175A (en
Inventor
孔庆忠
孙娟
贺润平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Lanjin Pharmaceuticals Co Ltd
Original Assignee
Jinan Shuaihua Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Shuaihua Pharmaceutical Technology Co Ltd filed Critical Jinan Shuaihua Pharmaceutical Technology Co Ltd
Priority to CN200610200997A priority Critical patent/CN1927175B/en
Publication of CN1927175A publication Critical patent/CN1927175A/en
Application granted granted Critical
Publication of CN1927175B publication Critical patent/CN1927175B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Disclosed is an compound anticancer slow release injection containing tetrazole Ionone, which comprises slow release micro-balloons and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. the anticancer active constituents being the combination of tetrazole lonone and tetrazole lonone synergistic agent selected from anti-cancer antibiotics and/or antimetabolites, the slow release auxiliary materials are selected from polylactic acid / glycollic acid copolymer, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid), poly(fumaric acid-sebacylic acid), Polifeprosan, EVAc or their combination, the viscosity of the suspension adjuvant is 80-3000cp. The slow release microspheres can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a release period of about 40 days. The slow release injection and slow release implanting agent can be used independently for effectively suppressing tumor accretion, or used in combination with non-operative methods such as chemotherapy and/or radiotheraphy with the function of improving their treatment effects.

Description

Contain the compound anti-cancer slow-release injected of tetrazole violet
(1) technical field
The present invention relates to a kind of compound anti-cancer slow-release injectedly, belong to technical field of pharmaceuticals.Particularly, the invention provides a kind of compound anti-cancer medicinal slow release agent that contains tetrazole violet and its synergist, be mainly slow releasing injection and sustained-release implant.
(2) background technology
Tetrazole violet is comparatively obvious to multiple malignant tumor action effects such as leukemia and entity tumors as the new chemotherapeutics of a class.Yet its tangible general toxicity has greatly limited the application of this medicine.
In addition, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fibrin and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy, be difficult to tumor by local and form effective drug level, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Qet al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.Pharmaceutical topical application may solve the problem (Chinese patent) of drug level to a certain extent, yet operation techniques such as medicine implantation are complicated, traumatic big, the various complication such as, infection hemorrhage, immunity reduction, also can cause or quicken the diffusion and the transfer of tumor except that easily causing.In addition, the preparation of perioperatively itself and expensive expense usually influence its effective enforcement.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth " (referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; etal., Int J Cancer.2004; 111 (4): 484-93)).
Therefore, be convenient to keep high drug level and increase tumor cell the preparation and the method for the sensitivity of medicine just become an important subject at tumor by local.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of slow-releasing anticarcinogen injection is provided, more specifically, is entity-tumor-resistant medicine composition, comprises slow releasing injection and sustained-release implant.
Anti-cancer medicine sustained-release injection of the present invention is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release microparticle, the one-tenth following by percentage by weight is grouped into:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 41-99.9%
Suspending agent 0.0-30%
(B) solvent is divided into common solvent and special solvent.
Anticancer effective component is tetrazole violet and tetrazole violet synergist, and described tetrazole violet synergist is selected from antitumor antibiotics and/or antimetabolitas.The cancer therapy drug decapacitation suppresses can also increase the sensitivity of tumor cell to tetrazole violet outside the tumor growth, therefore is called the tetrazole violet synergist again.
The present invention finds that many tetrazole violets and tetrazole violet synergist share its antitumaous effect is strengthened mutually; In addition, the compositions of tetrazole violet synergist and tetrazole violet is made drug level that anticancer medicine slow-release preparation containing (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduces the drug level of medicine in blood circulation, is reduced the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.
The drug main that tetrazole violet is made is wanted conventional route administrations such as oral administration or intravenous injection, and administering mode of the present invention is the local sustained release administration, obviously reduces the toxic action of its whole body in the therapeutic effect that significantly strengthens medicine.Slow-releasing system mainly is a slow-release auxiliary material.Pharmaceutic adjuvant have hundreds of more than, pharmaceutic adjuvant with slow releasing function, particularly the pharmaceutic adjuvant that selected tetrazole violet among the present invention slowly can be discharged in the regular hour in human body or animal body must could obtain through a large amount of creationary experiments, specific slow-release auxiliary material and can need be passed through a large amount of creative works by the selection of the combination of slow releasing pharmaceutical and could determine.The data of release characteristics need could obtain through a large amount of creationary experiments in inside and outside in the related data, particularly animal body, are not just can determine to have unobviousness through limited experiment.
The above unexpected main contents of the present invention of finding to constitute.
Slow-release auxiliary material range of viscosities IV (dl/g) is 0.1～0.8, be selected from poly-dl-lactide (D, L-PLA), poly-dl-lactide/ethanol copolymer (D, L-PLGA), monomethyl polyethylene glycol (MPEG-PLA), monomethyl polyethylene glycol copolymer (MPEG-PLGA), polyethylene glycol (PLA-PEG-PLA), polyethylene glycol copolymer (PLGA-PEG-PLGA), end carboxyl polylactic acid (PLA-COOH), end carboxyl polylactic acid/ethanol copolymer (PLGA-COOH), polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), PPDO (PDO), PTMC (PTMC), xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, one of albumin glue or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
Tetrazole violet comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate and maleate etc.
Tetrazole violet among the present invention also can be replaced by other tetrazolium salts or tetrazole violet analog; as; but be not limited to; Thiazolyl blue tetrazolium bromide; claim 3-4 again; 5-dimethylthiazole-2-base-2; 5-hexichol Thiazolyl blue tetrazolium bromide (MTT); Thiazolyl blue (TB:thiazolylblue; 2-(2 '-Benzothiazolyl)-5-styryl-3-(4 '-phthalhydrazidyl) tetrazoliumchloride); the tetrazolium orchid; claim dichloro 3 again; 3 '-[3; 3 '-dimethoxy (1; 1 '-biphenyl)-4; 4 '-two bases]-two [2; 5 biphenyl-2H-tetrazolium] (Tetrazolium Blue:3; 3 '-[3; 3 '-dimethoxy (1; 1 '-biphenyl)-4; 4 '-diyl]-bis[2; 5-diphenyl-2H-tetrazolium] dichloride); (1H)-tetrazolium (1H-tetrazole); Vitastain (1,3, the 5-Triphenyl Tetrazolium Chloride; or chlorination 2; 3, the 5-Triphenyl Tetrazolium Chloride) (tetrazolium red:1,3; 5-triphenyltetrazolium or 2; 3,5-triphenyltetrazoliumchloride); chlorination 2,3; 5-triphen-2-H-tetrazolium (2; 3,5-triphenyl-2-H-tetrazolium); chlorination 5-cyano group-2,3-two ditolyl tetrazolium (CTC:5-cyano-2; 3-ditolyl tetrazolium chloride); p-iodonitrotetrazolium violet; claim again (2-[4-allusion quotation benzene]-the 3-[4-Nitrobenzol]-5-phenyltetrazole chlorine) (INT:p-iodonitrotetrazolium violet or (2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium chloride); the nitro tetrazole violet; the chlorination iodonitrotetrazolium; tetrazole violet, the violet tetrazolium claims chlorination (2 again; 5-biphenyl-3-[Alpha-Naphthyl]-tetrazolium) (tetrazolium violet:2; 5-diphenyl-3-[α-naphthyl]-tetrazolium chloride; chlorination 2 (p-iodobenzene-p-Nitrobenzol-5-benzene tetrazolium (INPT:2-(p-iodophenyl)-p-itrophenyl-5-phenyltetrazolium chloride); the blue tetrazolium of chlorination p-nitro; the blue monotetrazolium of chlorination nitro; chlorination nitro neotetrazolum; Tetrazolium Nitro BT; the blue tetrazolium of chlorination; PIPERONYL TETRAZOLIUM BLUE (piperonyl tetrazolium blue); TOLYL TETRAZOLIUM RED (oTTR:o-Tolyltetrazolium red, or p-TTR:p-Tolyl tetrazolium red); neotetrazolium chloride (claims chlorination 2,2 ' again; 5; 5 '-four benzene-3,3 '-[p-two inferior benzene] two tetrazoliums) (neotetrazolium chloride:(NT:2,2 '; 5; 5 '-tetraphenyl-3,3 '-[p-diphenylene] ditetrazolium chloride); Tetrazolium Nitro BT also claims chlorination P-nitro blue tetrazolium; or chlorination 2; 2 '-two-Nitrobenzol-5,5 '-diphenyl-3,3 ' [3; 3 '-dimethoxy-4; 4 ' two phenylene]-two tetrazoliums (NBT:nitro blue tetrazolium or p-nitrotetrazolium blueor 2,2 ' di-p-nitrophenyl-5,5 '-diphenyl-3; 3 ' [3; 3 '-dimethoxy-4,4 ' diphenylene]-tetrazolium chloride); TNBT (TNBT:tetranitro blue tetrazolium); the blue tetrazolium (NBT:nitro blue tetrazolium) of nitro; chlorination 2,2 '-two [p-nitre benzene]-5; 5 '-two [p-thiocarbamoyl benzene]-3; 3 '-[3,3 '-dimethoxy-4,4 '-two inferior benzene] two tetrazolium (TC-NBT:2; 2 '-di[p-nitrophenyl]-5; 5 ' di[p-thiocarbamylphenyl]-3,3 '-[3,3 '-dimethoxy-4; 4 '-biphenylene] ditetrazolium chloride); claim Thiocarbamyl nitro-BT (thiocarbamyl nitroblue tetrazolium) again; tetrazotized o-dianisidine (TTD:tetrazotized O-dianisidine); 3-(4,5-dimethylthiazole-2-yl)-5-(3-carboxyl anisyl)-2-(4-sulfophenyl-2H-tetrazolium salts (MTS:3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt); 4-[3-(iodophenyl-2-(4-Nitrobenzol-2H-5-tetrazolium)-1; the 3-benzene disulfonate (WST-1:4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5tetrazolio]-1; 3-benzene disulfonate); 2,2-two (2-methoxyl group-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyl anilid (XTT:2,2-bis (2-methoxyl-4-notro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide); 1-[4; 5-dimethylthiazole-2-yl]-2; 5-hexichol Thiazolyl blue tetrazolium bromide (1-DDTT:1-[4,5-dimethylthiazol-2-yl]-2,5-iphenyltetrazolium bromide); 3 '-[1-[(phenyl amino-phosphinylidyne)]-3; the 4-tetrazolium]-two (4-methoxyl group-6-nitro) benzene-sulfo group acid sodium hydroxide (PCTT:sodium3 '-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene-sulfonic acid hydrate; p-Anisyl Blue Tetrazolium Chloride (pABT:p-Anisyl bleu tetrazolium chloride or pApNBT:p-Anisyl-p-nitro bleu tetrazolium chloride) or Herba chenopodii be basic tetrazolium orchid recklessly.
Above tetrazolium salts is with tetrazole violet (TV), Thiazolyl blue tetrazolium bromide (MTT), Thiazolyl blue (TB), the tetrazolium orchid, Vitastain, p-iodonitrotetrazolium violet (INT), the nitro tetrazole violet, the chlorination iodonitrotetrazolium, chlorination 2 (p-iodobenzene)-p-Nitrobenzol-5-benzene tetrazolium (INPT), the blue tetrazolium of chlorination p-nitro, the blue monotetrazolium of chlorination nitro, chlorination nitro neotetrazolum, the blue tetrazolium of chlorination, TOLYL TETRAZOLIUM RED (p-TTR), neotetrazolium chloride (NT), TNBT (TNBT), the blue tetrazolium (NBT) of nitro, TC-NBT, TTD, MTS, WST-1, XTT, 1-DDTT, 3-DDTT, PCTT, pABT or Herba chenopodii basic tetrazolium orchid recklessly are preferred.
Tetrazolium saltses such as tetrazole violet shared ratio in compositions is decided because of concrete condition, can be 0.1%-50%, is good with 1%-40%, and 5%-30% is best.
Antitumor antibiotics mainly is selected from carcinomycin, bleomycin (Bleomycin, Bleomycin A5, Pingyangmycin), (hydrochloric acid) bleomycin, zorbamycin, the piperazine bleomycin, sulphuric acid piperazine bleomycin, antibiotic 1588, bouvardin, kidamycin, acetylkitamycin (acetyl kidamycin), azotomycin (azotomycin), daunorubicin (rubidomycin, daunomycin, daunomycin), ciclamicin, Carzinocidin (carzinocidin), carzinophillin (carzinophylin), cardinophyllin, the tumor rhzomorph, carzinostatin (carzinostatin, carcinostain), neocarzinostain NCS (neocarzinostain), diazamycine (diazamycine), Macrocin (macrocin), macrocinomycin (macrocinomycin), dactinomycin, alanopsin, alazopeptin, the A Le lid, neothricin (neothricin, neothramycin), macromycin (macromomycin or macromycin), neothramycin A, nocardin (nocardin), nocardorubin. (nocardorubin), 2-[N-(2-amidinoethyl)carbamoyl (noformicin), nogalamycin (promise Garamycin, nogalamycin or nogaromycin), Mitochromine mitocromine B-35251 (mitochromine or mitocromine), polymyxin E (Polymyxin E), pirlimycin (Pirlimycin), dirithromycin (Dirithromycin), antramycin, oxalysine, duazomycin, Olivomycin, rufocromomycin, NSC-45384, streptozotocin, peplomycin, puromycin, sparsomycin, talisomycin, hydroxyl nitre D-glucosamine ring element, anthramycin (anthramycin, antramycin), methylanthramycin, Ai Fei ground can be peaceful, asperlin, (hydrochloric acid) Carrninomycin I, talisomycin, macromycin, O-Demethyldaunomycin, NSC-178248, chromomycin A3, demethylrifampicin, ditrisarubicins, Hitachimycin, deoxycoformycin, puromycin, puromycin hydrochloride, rachelmycin, rebeccamycin, Sangivamycin, sarkomycin, sibiromycin, talisomycin, rice holder Zuro, selenazofurin, Antibiotic BMG-162aF2, spirogermanium hydrochloride, Spirogermanium, Spirophydantoin Mustard, stibcytostatum, aclarubicin (aklavine, Aclacinomycin A), aklavine-B, darubicin (Idarubicin Hydrochloride, darubicin), Diacetoxysciroenol (Diacetoxysciroenol), clarithromycin (Clarithromycin), 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin (doxorubicin), epirubicin (Epirubicin), valrubicin (valrubicin), pirarubicin, Anthrapyrazole, losoxantrone (Losoxantrone), mitoxantrone (Mitoxantrone), piroxantrone (Piroxantrone), teloxantrone (Teloxantrone), chlorine assistant star (chlorozotocin).
In the above antitumor antibiotics, with bleomycin, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone, chlorine assistant star is preferred.
Above antitumor antibiotics medicine also comprises its salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
Above-mentioned antitumor antibiotic shared ratio in compositions is decided because of concrete condition, can be 0.1%-50%, is good with 1%-40%, and 2%-30% is best.
Antimetabolitas can stop the synthetic of DNA in different links respectively, suppresses cell division propagation, and cell cycle and DNA are synthetic to play a role by influencing.
Antimetabolitas is selected from one of following or combination: comprise, pemetrexed (Alimta), pemetrexed disodium, Rumi Qu Sai, tisupurin, Hydrazinium sulfate, dianhydrogalactitol, Aziridinyl Benzoquinone, but sweet smell Luoning, isoeuxanthone, chalone, chlorine is bent phosphoric acid, clastoban, cycloleucine, look into the Chinese holly woods, methyl yellow is looked into the Chinese holly woods sourly, Bai Ruikuaer, oxipurinol, Australia Ma Lite, bromine crust acid (sodium), Brytoslatin-I, bromine urea glycosides, fluorine urea hexylamine, 10-ethyl denitrification aminopterin deaza-aminopterin), 5, the 10-lonetrexol, N5-Methyltetrahydrohmofotic Acid, buthiopurin, his amide of Dinke, Guang azepine crow glycosides, 6-prenylindole, 6-thioinosine, coralyne, N-foymylsarcolysin, ammonia (base) pterin (aminopterin), aminopterin sodium (Aminopterin Sodium), 6-dimethylamino-8-azaadenosine, (nitro) imuran (azathioprine), azaserine (azaserine), Raltitrexed (Raltitrexed), nolatrexed dihydrochloride, sophoridine, formyl tetrahydrofolic acid, 5-methyltetrahydrohomofolate, Zoledronate, thunder accounts for for song, the temozolomide, bicalutamide, asparaginase (L-Asparaginase, left-handed asparagine), Quinespar, triazinate, trimetrexate, tramadol, the 5-chlorobarbituric acid, 5-diazonium uracil, piracetam, the 5-fluorouracil nucleoside, the 5-fluorouracil deoxynucleoside claims the fluorouracil deoxynucleoside again, glycerol Citrus chachiensis Hort. alkali, A Lei can loose, HCFU, 5 ' DFUR, TK-177, isoxazole acetic acid, aminoglutethimide (ethylbenzene amine piperidones, aminoglutethimidium, aminoglutethimide), amonafide, 5-chloro-5-deoxyarabinosylcytosine, atamestane, azacytidine (Azacitidine, 5-azacytidine, the atropic cytidine, AzGR), chloramphenalan (betamerphalan, Betamerphalan), decitabing, dexrazoxane (Dexrazoxane), crisnatol, cristatic acid, carat is sharp flat, the sharp guest of carat, zalcitabine, emtricitabine, galocitabine (Galocitabine), gemcitabine (Gemcitabine), ibacitabine (Ibacitabine), enocitabine (Enocitabine), ancitabine (Ancitabine), decitabine (Decitabine), flurocitabine (Flurocitabine), capecitabine (Capecitabine), his shore of imidazoles, the non-Shandong of Crane, the OK a karaoke club amide, carzolamide, carbazylquinone, CB-1-252, curcumin, the curcumin diketone, ketotrexate, trimetrexate, Si Poguning, deoxidation Si Poguning, naphthalene urea phosphamide, Ditercalinium Chloride, F-ara AMP-2, fluorine benzyl thiophene ketone, gamlogic acid, goserelin, nitrogen Chinese holly mountain range, Hellebrigenin, inosine dialdehyde, metoprine, mitobronitol (Dibromomannitol, Mitobronitol), mitolactol (Mitolactol), Ke is for ground, Persian, eriolangin, dopan (Chlorethylaminouracil, Dopan), Mei Luogerui, Methyl GAG, rice holder quinone, mitotane, fazarabine (Fazarabine), fludarabine (fludarabine), cladribine (cladribine), pentoside (pentostatin), phenaline, benzene comes U.S. special, phosphemide, hair Buddhist nun azoles, Polyprenic Acid, Pteroylaspartic Acid, pteroyltriglutamic acid, fast rice tongue pool, riboprine, simtrazene, Schizophyllan, sodium bromebrate, Solvent Yellow 3, bent fourth sulphur ester, TEM, triaziquone, triciribine, TCN-P NSC-280594, triptolide, triptorelin, nine cloth Lip river azoles, UFT, Wei Maining, z-azepine adenosine, prick western cytidine, epipropidine (Epipropidine), the A Monuo phase, adozelesin (Adozelesin), acronine (Acronine), alanosine (Alanosine), ametantrone (Ametantrone), Anastrozole, the A Naxi army, anaxirone (Anaxirone), A Si Yin wakes up, acivicin (Acivicin), atevirdine (Atevirdine), idoxifene (idoxifene), AT-236, hold high and rather study carefully Ji, individual Lu Dabuxin, antineoplaston, asaphan, Aspargus Granule, AT-346, Bai Ruikuaer (sodium), (hydrochloric acid) Orang Crush, granisetron, tropisetron, dacarbazine, ondansetron, thymosin, tramadol, imatinib mesylate, diclofenac, the holder fluorine kills star, toremifene, ambroxol, lappaconitine, anti-general etc. because of, thymosin, flutamide, ethyliminum, amine benzene, neoquini oxydum, the N-methylformamide, the jail can reach azoles, NSC-56045, oxisuran, oxylycorine, paphencyl, it is fixed to moor damp Nip, the penberol, prospidine chloride, protoanemonin, good generation born of the same parents, retelliptine, Sensorad, M3, solapalmitine, solaziquonum, stibenemidine, Temozoromide, the many Shillongs of platform, thiaolivacine, the pyridine of nitre ammonia bifurcation, 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one (nolatrexed dihydrochlormide) or SN-11841.
Above-mentioned antimetabolitas with his shore of pemetrexed, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine, thunder for song account for, Raltitrexed, dexrazoxane, cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one serve as preferred.
The percentage by weight of above-mentioned antimetabolitas in compositions is good from 1%-50% with 5%-30%.
When the cancer therapy drug in the medicament slow-release microsphere only is tetrazole violet or tetrazole violet synergist, slow-releasing anticarcinogen injection is mainly used in the tetrazole violet of other approach application of increase or the action effect of tetrazole violet synergist, or is used for the potentiation to radiotherapy or other therapies.When the cancer therapy drug in the medicament slow-release microsphere only was tetrazole violet or its synergist, the application of slow-releasing anticarcinogen injection and potentiation mode were:
(1) contain the slow releasing injection local injection of tetrazole violet, and the tetrazole violet synergist is used through other approach;
(2) local injection contains the slow releasing injection of tetrazole violet synergist, and other approach are used tetrazole violet;
(3) local injection contains the slow releasing injection and the slow releasing injection that contains the tetrazole violet synergist of tetrazole violet; Or
(4) local injection contains the slow releasing injection of tetrazole violet and synergist.
The slow-releasing anticarcinogen injection of topical application also is used for the potentiation to radiotherapy or other therapies.Other approach refer to, but, be not limited to tremulous pulse, vein, abdominal cavity, subcutaneous, intracavitary administration.
Anticancer effective component tetrazole violet and/or the percentage by weight of tetrazole violet synergist in medicament slow-release microsphere are 0.5%-60%, are good with 1%-40%, are best with 5%-30%.The weight ratio of tetrazole violet and tetrazole violet synergist is 1-9: 1 to 1: 1-9, with 1-2: 1 serves as preferred.
Anticancer effective component is a kind of or the combination of several tetrazole violets and/or a kind of or several anticarcinogens in the anticancer pharmaceutical composition of the present invention, and the anticancer effective component preferred compositions is as follows:
(a) tetrazole violet, p-iodonitrotetrazolium violet, nitro tetrazole violet and bleomycin, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(b) his shore of tetrazole violet, p-iodonitrotetrazolium violet, nitro tetrazole violet and pemetrexed, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, dexrazoxane, cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
Tetrazole violet percentage by weight concrete condition and deciding in compositions can be good with 1%-50% from 0.1%-60%, is best with 2%-40%.When tetrazole violet and cancer therapy drug use in conjunction, the weight ratio of the two can be 1: 9 to 9: 1.
Slow-release auxiliary material of the present invention can be through enzyme, soda acid or tissue fluid hydrolysis or degraded, comprises one of following or its combination:
(1) biocompatibility polymer comprises biodegradable or not biodegradable polymer and composition thereof or copolymer;
(2) water-soluble low-molecular chemical compound; Or/and
(3) be used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Slow-release auxiliary material is selected from poly-dl-lactide, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, one of gelatin and albumin glue or its combination.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release micro-spheres of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) EVAc of 55-90%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or white tempera; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA)), bis-fatty acid-decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid-decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 5,000-30,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 5,000-50,000 is preferred, with 10,000-30,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.Used polylactic acid serves as preferred with Poly-L-lactic acid (L-PLA).Poly-L-lactic acid (L-PLA) range of viscosities IV (dl/g) is 0.2～0.8, and glass transition temperature range is 55～65 ℃, 175～185 ℃ of fusing points.
Except that above-mentioned slow-release auxiliary material, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.; Also can add other pharmaceutic adjuvant, as but be not limited to filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain anticancer component is suspended in gained in the injection, used slow-release auxiliary material is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.Be convenient injection, the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or Tween 80 (0.1%) are dissolved in the normal saline corresponding solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, the certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid are first-selection, mixture and copolymer can be selected from, but be not limited to PLA, PLGA, the mixture of PLA and PLGA, the mixture or the copolymer of certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)].Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release implant of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) EVAc of 55-90%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or albumin glue; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.Can be the bar-shaped of 0.1-5mm (slightly) * 1-10mm (length), also can be other shapes such as lamellar.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
The anticancer effective component of sustained-release implant is preferably as follows, and all is weight percentage:
(a) tetrazole violet of 2-40%, p-iodonitrotetrazolium violet, the bleomycin of nitro tetrazole violet and 2-40%, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(b) tetrazole violet of 2-40%, p-iodonitrotetrazolium violet, the pemetrexed of nitro tetrazole violet and 2-40%, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, the temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, dexrazoxane, the combination of cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
Slow-release auxiliary material can be various water solublity or water-insoluble macromolecule polymer, copolymer (PLGA), ethylene vinyl acetate copolymer (EVAc), polifeprosan, bis-fatty acid and the decanedioic acid copolymer (PFAD-SA) of preferred polylactic acid (PLA), polyglycolic acid and hydroxyacetic acid, one of poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)] or its combination in multiple slow-release auxiliary material.
Route of administration depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.
The application of sustained-release implant and the same slow-releasing anticarcinogen injection of potentiation mode, the tetrazole violet synergist that place the associating of the tetrazole violet of the associating of the synergist of the promptly local tetrazole violet of placing and other administration, the local tetrazole violet synergist of placing and other administration, part and the associating of the local tetrazole violet of placing.Wherein the tetrazole violet synergist of topical application and tetrazole violet can be separately or Joint Production, packing, sale, use.Packing refers to medicine carrying process and pastille slow-release agent the exterior and interior packing for transport and/or store of medicine for adjuvant.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment the technology of composition for treating solid tumor of the present invention is further described:
Tumor-inhibiting action in the body of test one, tetrazole violet and tetrazole violet synergist.
With the rat is subjects, with 2 * 10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is tetrazole violet, and the 3rd to 6 group is respectively aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin.The the 7th to 10 group of associating that is respectively tetrazole violet and aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin.Except that tetrazole violet was placed in tumor, aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin were intraperitoneal administration.Dosage measuring is 5mg/kg except that tetrazole violet is 10mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 30th day.
Table 1
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 60±14
2(6) Tetrazole violet 38±8 ＜0.05
3(6) Aclarubicin 40±8 ＜0.05
4(6) Darubicin 46±10 ＜0.05
5(6) 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline 46±8 ＜0.01
6(6) Doxorubicin 48±8 ＜0.01
7(6) Tetrazole violet+aclarubicin 24±4 ＜0.001
8(6) Tetrazole violet+darubicin 26±5.6 ＜0.001
9(6) Tetrazole violet+9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline 26±4 ＜0.001
10(6) Tetrazole violet+doxorubicin 20±3.0 ＜0.001
Annotate: aclarubicin, darubicin, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin are the tetrazole violet synergist.The result shows, compares with matched group, and tetrazole violet (the 2nd group) and antitumor antibiotic (the 3rd to 6 group) application separately all have certain tumor-inhibiting action (P＜0.05), particularly topical.And use in conjunction (the 7th to 10 group) has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test two, tetrazole violet and tetrazole violet synergist.
With the rat is subjects, with 2 * 10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 2).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is tetrazole violet; The the 3rd to 6 group is cancer therapy drug.The the 7th to 10 group of associating that is respectively tetrazole violet and its synergist.Except that tetrazole violet was placed in tumor, epirubicin, valrubicin, pirarubicin, Anthrapyrazole were intraperitoneal administration.Drug dose is 2.5mg/kg except that tetrazole violet is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 2) on the 30th day.
Table 2
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 66±18
2(6) Tetrazole violet 48±5.0 ＜0.05
3(6) Epirubicin 62±2.3 ＜0.05
4(6) Valrubicin 54±3.6 ＜0.05
5(6) Pirarubicin 56±3.4 ＜0.05
6(6) Anthrapyrazole 50±3.8 ＜0.05
7(6) Tetrazole violet+epirubicin 26±3.4 ＜0.001
8(6) Tetrazole violet+valrubicin 26±3.2 ＜0.001
9(6) Tetrazole violet+pirarubicin 24±3.2 ＜0.001
10(6) Tetrazole violet+Anthrapyrazole 20±3.8 ＜0.001
Annotate: epirubicin, valrubicin, pirarubicin, Anthrapyrazole are the representative of antitumor antibiotic.Same potentiation also sees the combination of p-iodonitrotetrazolium violet or nitro tetrazole violet and above-mentioned antitumor antibiotic.
Test three, topical application tetrazole violet are to the potentiation of antibiotic kind anti-cancer drugs thing.
With the rat is subjects, with 2 * 10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is tetrazole violet, and the 3rd to 6 group is respectively aclarubicin, amycin, epirubicin and pirarubicin.The the 7th to 10 group of associating that is respectively tetrazole violet and aclarubicin, valrubicin, epirubicin or pirarubicin.All medicines are placed in being tumor, and metering is 5mg/kg except that tetrazole violet is 2mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 30th day.
Table 3
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 58±12
2(6) Tetrazole violet 48±10 ＜0.05
3(6) Aclarubicin 42±12 ＜0.01
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
4(6) Valrubicin 36±8 ＜0.01
5(6) Epirubicin 38±8 ＜0.01
6(6) Pirarubicin 34±8 ＜0.01
7(6) Tetrazole violet+aclarubicin 24±4.0 ＜0.001
8(6) Tetrazole violet+valrubicin 20±4.0 ＜0.001
9(6) Tetrazole violet+epirubicin 28±4 ＜0.001
10(6) Tetrazole violet+pirarubicin 28±3.8 ＜0.001
Annotate: aclarubicin, valrubicin, epirubicin and pirarubicin are the antibiotics cancer therapy drug.The result shows, compares with matched group, and tetrazole violet (the 2nd group) and antibiotics cancer therapy drug (the 3rd to 6 group) application separately all have certain tumor-inhibiting action (P＜0.05).Yet use in conjunction (the 7th to 10 group) has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test four, tetrazole violet and antibiotics cancer therapy drug.
Detected tumor-inhibiting action in the body of tetrazole violet and antibiotics cancer therapy drug according to test three method.The result shows tetrazole violet, p-iodonitrotetrazolium violet, nitro tetrazole violet and bleomycin, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or the independent application of chlorine assistant magnitude antitumor antibiotic all have obvious tumor-inhibiting action (P＜0.05).And use in conjunction has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test five, tetrazole violet and anti-metabolism cancer therapy drug.
With the rat is subjects, with 2 * 10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 4).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is tetrazole violet; The the 3rd to 6 group is respectively the antimetabolic anticarcinoma agent thing.The the 7th to 10 group of associating that is respectively tetrazole violet and different antimetabolic anticarcinoma agent things.Except that tetrazole violet was placed in tumor, zalcitabine, pemetrexed, Rumi Qu Sai and emtricitabine were intraperitoneal administration.The dosage measuring tetrazole violet is that 4mg/kg is 5mg/kg outward.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 4) on the 30th day.
Table 4
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 70±14
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
2(6) Tetrazole violet 34±6 ＜0.05
3(6) Zalcitabine 54±8.0 ＜0.01
4(6) Pemetrexed 60±8.2 ＜0.01
5(6) Rumi Qu Sai 62±9.4 ＜0.01
6(6) Emtricitabine 56±6.8 ＜0.01
7(6) Tetrazole violet+zalcitabine 14±2.2 ＜0.001
8(6) Tetrazole violet+pemetrexed 20±3.6 ＜0.001
9(6) Tetrazole violet+Rumi Qu Sai 18±3.0 ＜0.001
10(6) Tetrazole violet+emtricitabine 16±2.0 ＜0.001
Annotate: zalcitabine, pemetrexed, Rumi Qu Sai and emtricitabine are the anti-metabolism cancer therapy drug.
Tumor-inhibiting action in the body of test six, tetrazole violet and anti-metabolism cancer therapy drug.
With the rat is subjects, with 2 * 10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 5).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is tetrazole violet, and the 3rd to 6 group is respectively the anti-metabolism cancer therapy drug.The the 7th to 10 group of associating that is respectively tetrazole violet and different anti-metabolism cancer therapy drugs.Except that tetrazole violet was placed in tumor, carmofur, ftorafur, gemcitabine and Raltitrexed were intraperitoneal administration.Except that being 4mg/kg, tetrazole violet is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 30th day.
Table 5
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 70±18
2(6) Tetrazole violet 36±4.0 ＜0.05
3(6) Carmofur 44±3.3 ＜0.01
4(6) Ftorafur 40±3.4 ＜0.01
5(6) Gemcitabine 42±3.4 ＜0.01
6(6) Raltitrexed 44±3.8 ＜0.01
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
7(6) Tetrazole violet+carmofur 28±3.8 ＜0.001
8(6) Tetrazole violet+ftorafur 20±3.4 ＜0.001
9(6) Tetrazole violet+gemcitabine 18±3.0 ＜0.001
10(6) Tetrazole violet+Raltitrexed 22±3.0 ＜0.001
Annotate: carmofur, ftorafur, gemcitabine and Raltitrexed are the anti-metabolism cancer therapy drug.
Similar potentiation also sees the associating of other tetrazole violet and other anti-metabolism cancer therapy drug, as: his shore of tetrazole violet, p-iodonitrotetrazolium violet or nitro tetrazole violet and pemetrexed, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, imidazoles, capecitabine, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, dexrazoxane, cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
With multiple other tumor cell (comprising the cerebral tumor (CNS-1, C6,9L), gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma, cancer of pancreas, renal carcinoma and the esophageal carcinoma etc.) is that subjects draws similar results.
Release ratio in the body of the tetrazole violet sustained-release implant that test 8, different molecular weight polylactic acid are made
With the rat is subjects, grouping (3/group) and the equivalent tetrazole violet sustained-release implant that carries in the subcutaneous polylactic acid (PLA) that contains different molecular weight (MW).Survey the surplus of medicine in implant respectively at 1,3,7,14,21,28 and 35 day then, and then draw rate of release (%) in its body.The result shows, molecular weight is 20000 is released to: 1 day (10%), 3 (26%), 7 (54%), 14 (84%), 21 (90), 28 (92) and 35 (96%).Discharge in the body of the tetrazole violet sustained-release implant that comparison different molecular weight polylactic acid is made and find, slack-off with the molecular weight increase, with the 7th day was example, compare with whole body administration group, tumor control rate increases with the polylactic acid molecule amount and improves, and is followed successively by 66% (MW:5000), 62% (MW:15000), 54% (MW:25000), 50% (MW:40000) and 44 (MW:60000).
It is the slow releasing agent that adjuvant is made that same result also sees with polylactic acid, contains the combination of tetrazole violet and its synergist.
That pays special attention to is simple to operation, the good reproducibility of slow releasing agent of the present invention, particularly slow releasing injection.Good effect not only, toxic and side effects is little.
Different drug packages is in the characteristic difference of the different prepared slow releasing agents of Biodegradable high molecular, different medicines and or the slow releasing preparation made of medicine not necessarily can satisfied release medicine.Of the present inventionly discover that further the slow-release auxiliary material that is most appropriate to medicament slow release of the present invention is a poly-dl-lactide, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, one of albumin glue or its combination; Optimum suspending agent is one of methylcellulose, hydroxy methocel, sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40, soil temperature 80 or its combination.
In a word, experimental result shows that tetrazole violet among the present invention is to the potentiation of listed anti-metabolism cancer therapy drug or antibiotics cancer therapy drug.Therefore, the effective ingredient of anticancer compound of the present invention is tetrazole violet and any one (or multiple) anti-metabolism cancer therapy drug and or the associating of antibiotics cancer therapy drug or packing separately.Above effective ingredient can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing type, is mainly slow releasing injection or sustained-release implant.
(4) specific embodiment
Embodiment 1.
With 80mg molecular weight peak value is that 25000 polylactic acid (PLA) is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg tetrazole violet and 10mg gemcitabine, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the anticancer slow-release of 10% tetrazole violet and 10% gemcitabine.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 14-21 days, is 25-45 days at the subcutaneous drug release time of mice.
Embodiment 2.
As described in embodiment 1, different is anticancer effective component and percentage by weight is one of following:
(a) tetrazole violet of 2-40%, the bleomycin of p-iodonitrotetrazolium violet or nitro tetrazole violet and 2-40%, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(b) tetrazole violet of 2-40%, the pemetrexed of p-iodonitrotetrazolium violet or nitro tetrazole violet and 2-40%, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, the temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, dexrazoxane, the combination of cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
Used macromolecule is poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Embodiment 3.
80mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add the 100ml dichloromethane, behind the dissolving mixing, add 10mg tetrazole violet and 10mg doxorubicin, shake up the back contains 10% tetrazole violet and 10% doxorubicin with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection, viscosity is 20cp-300cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 4.
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained anticancer effective component and percentage by weight thereof are:
(a) tetrazole violet of 5-30%, the bleomycin of p-iodonitrotetrazolium violet or nitro tetrazole violet and 5-30%, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(b) tetrazole violet of 5-30%, the pemetrexed of p-iodonitrotetrazolium violet or nitro tetrazole violet and 5-30%, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, the temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, dexrazoxane, the combination of cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
The viscosity of slow releasing injection is 10cp-650cp (20 ℃-30 ℃ time).
Embodiment 5.
With 70mg molecular weight peak value is that 25000 polylactic acid (PLGA, 75: 25) is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 15mg valrubicin and 15mg p-allusion quotation nitro tetrazole violet, shakes up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 15% valrubicin and 15%p-allusion quotation nitro tetrazole violet, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection, viscosity is 220cp-340cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 6
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that contained anticancer effective component and percentage by weight thereof are: the tetrazole violet of 2-40%, the bleomycin of p-iodonitrotetrazolium violet or nitro tetrazole violet and 2-40%, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; The viscosity of injection is 10cp-650cp (20 ℃-30 ℃ time).
Embodiment 7.
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg tetrazole violet and 10mg capecitabine, shake up the back contains 20% tetrazole violet and 10% capecitabine with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection, viscosity is 180cp-260cp (25 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that contained anticancer effective component is: the tetrazole violet of 5-30%, the pemetrexed of p-iodonitrotetrazolium violet or nitro tetrazole violet and 5-30%, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, the temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the combination of dexrazoxane or cladribine; Viscosity is 400cp-560cp (25 ℃-30 ℃ time).
Embodiment 9
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg pirarubicin and 10mg tetrazole violet, shake up the back contains 20% pirarubicin and 10% tetrazole violet with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection, viscosity is 100cp-160cp (25 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that contained anticancer effective component is: the combination of the aclarubicin of 15% tetrazole violet, p-iodonitrotetrazolium violet or nitro tetrazole violet and 15%, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star; Viscosity is 560cp-640cp (25 ℃-30 ℃ time).
Embodiment 11
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 15mg mitoxantrone and 15mg tetrazole violet, shake up the back contains 15% mitoxantrone and 15% tetrazole violet with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that used slow-release auxiliary material is: poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] or poly-(fumaric acid-decanedioic acid) [P (FA-SA)].
Embodiment 13
With 70mg molecular weight peak value 35000 polylactic acid (PLGA, 50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg valrubicin and 20mg nitro tetrazole violet, shake up the back contains 10% valrubicin and 20% nitro tetrazole violet with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
The method step that is processed into sustained-release implant is identical with embodiment 11-13, but different is that contained anticancer effective component and percentage by weight are:
(a) tetrazole violet of 5-30%, the bleomycin of p-iodonitrotetrazolium violet or nitro tetrazole violet and 5-30%, daunomycin, diethoxy acetyl amycin, nocardin, nocardorubin., 2-[N-(2-amidinoethyl)carbamoyl, nogalamycin, Mitochromine mitocromine B-35251, polymyxin E, pirlimycin, dirithromycin, antramycin, peplomycin, puromycin, sparsomycin, anthramycin, Carrninomycin I, puromycin, aclarubicin, aklavine-B, darubicin, Diacetoxysciroenol, clarithromycin, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, doxorubicin, epirubicin, valrubicin, pirarubicin, Anthrapyrazole, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(b) tetrazole violet of 5-30%, the pemetrexed of p-iodonitrotetrazolium violet or nitro tetrazole violet and 5-30%, pemetrexed disodium, Rumi Qu Sai, carmofur, ftorafur, the temozolomide, zalcitabine, emtricitabine, galocitabine, ibacitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, dexrazoxane, the combination of cladribine or 2-Amino-6-methyl-5-(pyridin-4-ylsulfanyl)-3H-quinazolin-4-one.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) polylactic acid (PLA), the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
B) copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50, the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
C) ethylene vinyl acetate copolymer (EVAc);
D) polifeprosan, to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) bis-fatty acid and decanedioic acid copolymer (PFAD-SA);
F) poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)];
G) poly-(fumaric acid-decanedioic acid) [P (FA-SA)];
H) xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or white tempera;
I) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 1-10, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.
Above result shows that the tetrazole violet that the present invention is used and the combination of its synergist are of universal significance.Therefore, the tumor tetrazole violet dosage of slow-releasing anticarcinogen injection of the present invention is chosen as arbitrarily.Equally, the associating of tetrazole violet and its synergist also is arbitrarily.Can further draw on the basis that is chosen in available data of the present invention of relevant dose.
Above embodiment only is used for explanation, and also unrestricted application of the present invention.

Claims (1)

1. one kind contains the compound anti-cancer slow-release injected of tetrazole violet, and the component that it is characterized in that described slow releasing injection is following combination:
Anticancer effective component is that 10% tetrazole violet and 10% doxorubicin, slow-release auxiliary material are 80% polifeprosan in the sustained-release micro-spheres, wherein, in the polifeprosan to carboxy phenyl propane: decanedioic acid is 20: 80, and solvent is the normal saline that contains 15% mannitol.
CN200610200997A 2006-10-16 2006-10-16 Compound recipe anticancer slow release injection comprising tetrazole violet Expired - Fee Related CN1927175B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200610200997A CN1927175B (en) 2006-10-16 2006-10-16 Compound recipe anticancer slow release injection comprising tetrazole violet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200610200997A CN1927175B (en) 2006-10-16 2006-10-16 Compound recipe anticancer slow release injection comprising tetrazole violet

Publications (2)

Publication Number Publication Date
CN1927175A CN1927175A (en) 2007-03-14
CN1927175B true CN1927175B (en) 2010-05-19

Family

ID=37857411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610200997A Expired - Fee Related CN1927175B (en) 2006-10-16 2006-10-16 Compound recipe anticancer slow release injection comprising tetrazole violet

Country Status (1)

Country Link
CN (1) CN1927175B (en)

Also Published As

Publication number Publication date
CN1927175A (en) 2007-03-14

Similar Documents

Publication Publication Date Title
CN1861055A (en) Composite slow-releasing anticarcinogen injection contg. platinum compounds
CN100998553A (en) Compound anticarcinogen slow-release preparation containing vasoinhibitor
CN1923173B (en) Anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
CN100374160C (en) Anti-cancer medicine composition containing antimetabolite
CN100500219C (en) Anti tumour medicinal composition containing platinum compound
CN1969820A (en) Anticancer pharmaceutical composition
CN101023923A (en) Anti-cancer slow-release agent containing glucocorticoid hormone
CN1927175B (en) Compound recipe anticancer slow release injection comprising tetrazole violet
CN100500212C (en) Anti entity tumour medicinal composition
CN1969825A (en) Sustained release agent containing fluorouracil and synergist thereof
CN1857723A (en) Slow released anticancer medicine preparation with both amrubicin and its synergist
CN100500218C (en) Anti tumour medicinal composition
CN1973820A (en) Anticancer composition containing Sirolimus and its application
CN1969817A (en) Anticancer composition
CN1961862A (en) Compound anticancer sustained releasing agent containing mesenchyme hydrolytic reagent
CN101352413A (en) Compound anticancer sustained-release injection containing clofarabine
CN101390828B (en) Anticancer composition loaded with anti-metabolism medicine and synergist thereof
CN1969823A (en) Sustained release agent containing fluorouracil and synergist thereof
CN101327185A (en) Anticancer sustained-release implantation agent
CN1969824A (en) Anticancer sustained release agent containing fluorouracil and synergist thereof
CN100500216C (en) Anti entity tumour medicinal composition containing dichloro ethamine kind drug
CN1887261A (en) Slow released compound anticancer injection containing bendamustine
CN1923284A (en) Anti-cancer drug slow release injection and uses thereof
CN101371821A (en) Anti-cancer medicine composition containing metabolism-resistance medicament
CN1957920B (en) Anti cancer slow release agent carrying fluorouracil and synergist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan

Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

ASS Succession or assignment of patent right

Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD.

Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD.

Effective date: 20120815

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120815

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100519

Termination date: 20161016

CF01 Termination of patent right due to non-payment of annual fee